Key Points
- Insider sale: Tajinder Vohra sold 7,330 Revvity shares for approximately $1.03 million, reducing their direct ownership by 52.49% to 6,635 shares.
- Quarterly performance: Revvity reported adjusted earnings of $1.41 per share, exceeding estimates of $1.21, while revenue of $729.69 million also topped expectations but declined 1.3% year over year.
- Market outlook: Analysts have a consensus “Hold” rating and an average price target of $116.57, below the stock’s reported $143.60 price; the company also announced a quarterly dividend of $0.07 per share.
Revvity Inc. (NYSE:RVTY - Get Free Report) insider Tajinder Vohra sold 7,330 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the completion of the sale, the insider directly owned 6,635 shares of the company's stock, valued at $934,738.80. The trade was a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Revvity Price Performance
RVTY opened at $143.60 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The company has a market capitalization of $16.02 billion, a price-to-earnings ratio of 68.38, a P/E/G ratio of 2.67 and a beta of 1.09. The firm's fifty day moving average price is $120.62 and its two-hundred day moving average price is $104.72. Revvity Inc. has a 1 year low of $81.22 and a 1 year high of $149.52.
Revvity (NYSE:RVTY - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the prior year, the business posted $1.18 EPS. The business's revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts anticipate that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.
Revvity Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity's dividend payout ratio is currently 13.33%.
Institutional Investors Weigh In On Revvity
Several institutional investors have recently added to or reduced their stakes in the business. Ascentis Independent Advisors purchased a new position in shares of Revvity in the first quarter worth about $29,000. Global Retirement Partners LLC purchased a new stake in shares of Revvity during the 2nd quarter valued at approximately $51,000. SJS Investment Consulting Inc. boosted its holdings in Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock worth $47,000 after buying an additional 521 shares during the period. Summit Securities Group LLC boosted its holdings in Revvity by 294.6% in the 1st quarter. Summit Securities Group LLC now owns 663 shares of the company's stock worth $58,000 after buying an additional 495 shares during the period. Finally, Contravisory Investment Management Inc. purchased a new position in Revvity in the 1st quarter valued at approximately $66,000. 86.65% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of research firms have recently commented on RVTY. Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 16th. TD Cowen restated a "buy" rating on shares of Revvity in a report on Wednesday, July 15th. Wolfe Research assumed coverage on shares of Revvity in a research report on Tuesday, June 2nd. They issued a "peer perform" rating on the stock. Zacks Research upgraded shares of Revvity from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised shares of Revvity from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Thursday, July 30th. Four research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company's stock. According to data from MarketBeat.com, Revvity has a consensus rating of "Hold" and a consensus target price of $116.57.
View Our Latest Stock Report on Revvity
Revvity Company Profile
(
Get Free Report)
Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.
The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.
Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
